Donepezil for Dementia with Lewy Bodies: A Randomized, Placebo-Controlled Trial
Objective: Because cholinergic deficits are prominent in dementia with Lewy bodies (DLB), we investigated the effects of a cholinesterase inhibitor, donepezil, in such patients in a randomized, double-bilnd- placebo-controlled exploratory phase 2 trial.
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Wiley Subscription Services, Inc., A Wiley Company
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504981/ |